Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Plus Therapeutics Inc PSTV

Healthcare Biotechnology
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma... see more

Recent & Breaking News (NDAQ:PSTV)

Cytori Reports First Quarter 2016 Business and Financial Results

Business Wire May 10, 2016

Cytori Granted Broad European Orphan Drug Designation

Business Wire May 10, 2016

Cytori ATHENA Trial Results Support Symptomatic Benefit From Cytori Cell Therapy

Business Wire May 6, 2016

Cytori Reports Preliminary Preclinical Data Supporting Use of Cytori Cell Therapy™ for Both the Prevention and Treatment of Hypertrophic Scars

Business Wire May 5, 2016

Cytori to Webcast First Quarter Financial Results on May 10

Business Wire April 29, 2016

Cytori Announces Timing for Full Enrollment in U.S. Phase III Scleroderma Trial

Business Wire April 27, 2016

Top Penny Stocks: Four Trending Small Cap Stocks That Require Your Attention on April 18th 2016

Accesswire April 18, 2016

Cytori Strengthens Global Patent Portfolio

Business Wire April 18, 2016

Cytori Therapeutics to Present Preliminary Safety and Efficacy Preclinical Data at the 2016 American Burn Association Meeting

Business Wire April 14, 2016

Put These on Your Stocks to Watch List for Thursday 3/24/2016, If You Choose

Accesswire March 24, 2016

Cytori Update on Its U.S. Phase III Scleroderma Trial

Business Wire March 24, 2016

Cytori Granted SME Status by European Medicines Agency

Business Wire March 23, 2016

Cytori Reports Fourth Quarter and Full Year 2015 Business and Financial Results

Business Wire March 3, 2016

Data Reports Sustained Benefit at Two Years with Single Administration Cytori Cell Therapy for Scleroderma

Business Wire February 22, 2016

Cytori Management to Discuss Scleroderma Clinical Trial Findings

Business Wire February 19, 2016

Scleroderma Two Year Data to be Presented at the 4th Systemic Sclerosis World Congress

Business Wire February 10, 2016

Cytori Reports Interim Data on U.S. Phase II Osteoarthritis Trial

Business Wire February 8, 2016

Cytori Provides Latest Corporate Update at Source Capital Conference

Business Wire February 4, 2016

Cytori Cell Therapy Safe and Potentially Effective in EU Phase I Erectile Dysfunction Trial

Business Wire February 3, 2016

Cytori Update on Its U.S. Phase III Scleroderma Trial

Business Wire January 25, 2016